histone deacetylase

Type: Keyphrase
Name: histone deacetylase
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

Ending HIV: The Kick and Kill approach may prove a breakthough to cure

HIV researchers and scientists are hailing a new treatment study by Danish researcher Ole Schmeltz Søgaard, of Aahus University as a breakthrough in the search for a cure for HIV.Speaking at a press conference, Schmeltz Søgaard revealed his recent study ... [Published Gay News Network - Jul 22 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

Use of histone deacetylase inhibitors in changing MRJP3 protein in royal jelly

The invention provides a method of changing a ratio of 68 to 64 kDa protein of MRJP3 in a royal jelly, a method of producing a royal jelly comprising MRJP3 having a changed ratio of 68 to 64 kDa protein relative to a control royal jelly and the royal ... [Published Free Patents Online - Jul 22 2014]
First reported Jul 15 2014 - Updated Jul 15 2014 - 1 reports

Hydroxamates as therapeutic agents

The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone ... [Published Free Patents Online - Jul 15 2014]
First reported Jul 10 2014 - Updated Jul 10 2014 - 1 reports

Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment

Previous studies have shown that class-I histone deacetylase (HDAC) 8 mRNA is upregulated in urothelial cancer tissues and urothelial cancer cell lines compared to benign controls. Using urothelial cancer cell lines we evaluated whether specific targeting ... [Published 7thSpace - Jul 10 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 1 reports

UC Merced professor studies how disease spreads, resistance to drugs

Professor Clarissa J. Nobile, who studies microbial communities, has discovered mechanisms that allow a potentially fatal biofilm to spread and resist drugs.Her research was published last month in mBio, an open-access online journal by the American Society ... [Published Merced Sun-Star - Jul 09 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 1 reports

Development of a Fluorogenic Probe Based on a DNA Staining Dye for Continuous Monitoring of the Histone Deacetylase Reaction

We designed a simple, rapid, and continuous method for the detection of the activity of histone deacetylases (HDACs), which are key enzymes involved in epigenetic gene regulation, using a DNA-based fluorogenic probe. We designed and synthesized a fluorogenic ... [Published Analytical Chemistry - Jul 09 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 1 reports

FDA approves belinostat for peripheral T-cell lymphoma

Belinostat, a histone deacetylase inhibitor, has been approved for treating peripheral T-cell lymphoma, based on the results of the BELIEF study that found an overall response rate of nearly 26%... ... [Published Cardiology News - Jul 09 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 1 reports

1,3,4-Oxadiazole-Containing Histone Deacetylase Inhibitors: Anticancer Activities in Cancer Cells

† Department of Drug Chemistry and Technologies, Sapienza University of Rome, P. le A. Moro 5, 00185 Rome Italy‡ Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144 Rome, Italy§ Department of Biochemistry, Biophysics and General Pathology, ... [Published Journal of Medicinal Chemistry - Jul 08 2014]
First reported Jul 07 2014 - Updated Jul 07 2014 - 1 reports

Spectrum Pharma Gets FDA's Accelerated Approval For T-Cell Cancer Drug Beleodaq

Spectrum Pharmaceuticals Inc. (SPPI: Quote) Monday said that the U.S. Food and Drug Administration or FDA has granted accelerated approval for its T-cell lymphoma drug Beleodaq. The approval was based on Tumor Response Rate and Duration of Response. However, ... [Published RTTNews.com - Jul 07 2014]
First reported Jul 05 2014 - Updated Jul 05 2014 - 1 reports

FDA approves new HDAC inhibitor

The US Food and Drug Administration has approved a new histone deacetylase (HDAC) inhibitor developed by Topotarget of Denmark to treat patients with peripheral T cell lymphoma (PTCL), a rare and fast-growing type of non-Hodgkin lymphoma.LocationUnited ... [Published MedNous - Jul 05 2014]
First reported Jul 03 2014 - Updated Jul 03 2014 - 1 reports

Beleodaq OK'd for Rare Form of NHL

WASHINGTON (MedPage Today) -- The FDA has approved the histone deacetylase inhibitor belinostat for treatment of peripheral T-cell lymphoma, an uncommon but aggressive form of non-Hodgkin's lymphoma (NHL). ... [Published MedPageToday.com - medical news plus CME for ph ... - Jul 03 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 1 reports

Three-Drug Combo Improves Multiple Myeloma Response

Multiple Myeloma News From MilanHello. My name is Dr. Paul Richardson, and I am the RJ Corman Professor of Medicine at Harvard Medical School and Clinical Director of the Dana-Farber Cancer Institute in Boston, Massachusetts. Welcome to this edition of ... [Published General Medicine eJournal - Jul 01 2014]

Quotes

...advance the technology to include molecularly targeted therapies in 2015," said Scott Jackson, Chief Executive Officer of Celator Pharmaceuticals. "We also are broadening the potential use of CPX-351 primarily through investigator-initiated studies, and exploring its use in special AML populations, such as patients who are unfit for standard induction therapy, as well as other hematological malignancies such as myelodysplasia. Regarding our Phase 3 pivotal study of CPX-351 in patients with secondary AML, we expect to complete enrollment in the fourth quarter of 2014, which would keep us on track to report initial data in the second quarter of 2015."
"Activation and the HIV reservoirs are really the 2 critical determinants of HIV pathogenicity," Dr. Barré-Sinoussi told reporters. "This is another study showing that activation should be considered as a future strategy aiming for a cure, or at least a sustainable remission, in HIV patients without any treatment."
"In various embodiments, the patient treated has been identified as having a cancer with a low level of HDR activity. As demonstrated according to this invention, the lower the HDR activity in the cell, the more susceptible the cancer is to treatment with TH-302 or other hypoxia activated prodrugs with similar mechanism of action, and the higher the HDR activity in the cell, the less susceptible the cancer is to treatment with TH-302 or the other hypoxia activated prodrug. Conversely, however, patients with high HDR activity levels will benefit from treatment in accordance with the methods of the invention, relative to a treatment comprising a hypoxia activated prodrug that excludes an HDR inhibitor. Thus, patients suitable for treatment in accordance with the methods of the invention include those having cancer with any detectable level of HDR activity. Any known method for assessing HDR activity is suitable for use according to the present methods."

More Content

All (76) | News (68) | Reports (0) | Blogs (6) | Audio/Video (0) | Fact Sheets (0) | Press Releases (2)
sort by: Date | Relevance
Glucocerebrosidase Is Shaking Up the Synucleino... [Published General Medicine eJournal - Jul 25 2014]
Apicidin F: Characterization and Genetic Manipu... [Published Plosone.org - Jul 24 2014]
Belinostat for Relapsed/Refractory Peripheral T... [Published The ASCO Post - Jul 24 2014]
Multiple Myeloma Studies Explore Roles of Panob... [Published The ASCO Post - Jul 23 2014]
FDA Approves Belinostat for Relapsed or Refract... [Published The ASCO Post - Jul 23 2014]
Romidepsin activates latent HIV, but does not d... [Published Aidsmap - Jul 22 2014]
Ending HIV: The Kick and Kill approach may prov... [Published Gay News Network - Jul 22 2014]
Use of histone deacetylase inhibitors in changi... [Published Free Patents Online - Jul 22 2014]
CPXX: Update on CPX-351 and Technology Platform... [Published Yahoo! Finance - Jul 21 2014]
AIDS 2014: towards a cure [Published Gay News Network - Jul 21 2014]
Antitumor Effects of a Sirtuin Inhibitor, Tenov... [Published Plosone.org - Jul 17 2014]
Celator(R) Pharmaceuticals Provides Update on C... [Published Virtual Strategy Magazine - Jul 17 2014]
Mundipharma EDO GmbH shows strong preclinical a... [Published Hospital Pharmacy Europe - Jul 15 2014]
Hydroxamates as therapeutic agents [Published Free Patents Online - Jul 15 2014]
Managing Radioactive Iodine-Refractory Thyroid ... [Published General Medicine eJournal - Jul 15 2014]
Assessing cellular efficacy of bromodomain inhi... [Published 7thSpace - Jul 13 2014]
Epigenetic Changes in p21 Expression in Renal C... [Published Toxicological Sciences - Jul 12 2014]
Latest HIV Cure Data Expected at AIDS 2014, Mor... [Published Diabetes Care - Jul 11 2014]
Overexpression of miR-19b Impairs Cardiac Devel... [Published Sexual Development - Jul 11 2014]
Histone deacetylase 8 is deregulated in urothel... [Published 7thSpace - Jul 10 2014]
p53 activates SIRT6 to regulate gluconeogenesis... [Published PNAS - Jul 10 2014]
"Methods for Treating Cancer" in Patent Applica... [Published Pharmacy Choice - Jul 09 2014]
UC Merced professor studies how disease spreads... [Published Merced Sun-Star - Jul 09 2014]
Development of a Fluorogenic Probe Based on a D... [Published Analytical Chemistry - Jul 09 2014]
4-Phenylbutyric Acid Increases GLUT4 Gene Expre... [Published Sexual Development - Jul 09 2014]
FDA approves belinostat for peripheral T-cell l... [Published Cardiology News - Jul 09 2014]
1,3,4-Oxadiazole-Containing Histone Deacetylas... [Published Journal of Medicinal Chemistry - Jul 08 2014]
Distal Renal Tubules Are Deficient in Aggresome... [Published Plosone.org - Jul 08 2014]
FDA Grants Spectrum Pharmaceuticals Accelerated... [Published PharmaceuticalProcessing - Jul 07 2014]
Spectrum Pharma Gets FDA's Accelerated Approval... [Published RTTNews.com - Jul 07 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Beleodaq OK'd for Rare Form of NHL [Published MedPageToday.com - medical news plus CME for ph ... - Jul 03 2014]
WASHINGTON (MedPage Today) -- The FDA has approved the histone deacetylase inhibitor belinostat for treatment of peripheral T-cell lymphoma, an uncommon but aggressive form of non-Hodgkin's lymphoma (NHL). ...
Curis announces US patent issuance covering CUD... [Published PBR - News - May 02 2014]
Curis announced the issuance of US Patent No. 8,710,219 entitled ‘Phosphoinositide 3-kinase inhibitor with a zinc binding moiety’ that covers composition-of-matter for CUDC-907, the companty's dual histone deacetylase (HDAC) and phosphoinositide 3-kinase ...
[tt] [GRG] First disease-specific human embryon... [Published TranshumanTech - Apr 30 2014]
http://www.nature.com/nature/journal/vaop/ncurrent/full/nature13287. html Human oocytes reprogram adult somatic nuclei of a type 1 diabeticto diploid pluripotent stem cellsMitsutoshi Yamada,Bjarki Johannesson,Ido Sagi,Lisa Cole Burnett,Daniel H. Kor ...
New conversation on sociotechnical systems [Published MIT News feed - Apr 28 2014]
The MIT Sociotechnical Systems Research Center invites you to its next spring seminar in the "Conversations on Sociotechnical Systems" series on Wed., April 30, from 4:15-5:30 p.m. in Building E38-615. Light refreshments will be served. Traumatic ...
Histone Deacetylase Inhibitors: Emerging Markets [Published PR Newswire: Health - Apr 21 2014]
WEST HARTFORD, Conn., April 21, 2014 /PRNewswire-iReach/ -- Global Information Inc. announces the addition of a new market research report "Histone Deacetylase Inhibitors: Emerging Markets" at GIIResearch.comThe global histone deacetylase inhibitor (HDI) ...
1 2

Press Releases

sort by: Date | Relevance
New Japanese Patents Issued Covering Sapacitabi... [Published GlobeNewswire: Acquisitions News - May 05 2014]
Mirati Therapeutics to Present at the 25th Annu... [Published PR Newswire - Nov 22 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.